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Abstract
This study was conducted to investigate serum amino acids profile in dextran sulfate sodium (DSS)-induced colitis, and
impacts of graded dose of arginine or glutamine supplementation on the colitis. Using DSS-induced colitis model, which is
similar to human ulcerative colitis, we determined serum profile of amino acids at day 3, 7, 10 and 12 (5 days post DSS
treatment). Meanwhile, effects of graded dose of arginine (0.4%, 0.8%, and 1.5%) or glutamine (0.5%, 1.0% and 2.0%)
supplementation on clinical parameters, serum amino acids, colonic tight junction proteins, colonic anti-oxidative indicators
[catalase, total superoxide dismutase (T-SOD), glutathione peroxidase (GSH-Px)], colonic pro-inflammatory cytokines
[interleukin-1 beta (IL-1b), IL-6, IL-17 and tumor necrosis factor alpha (TNF-a)] in DSS-induced colitis were fully analyzed at
day 7 and 12. Additionally, the activation of signal transduction pathways, including nuclear factor kappa B (NF-kB),
mitogen-activated protein kinases (MAPK), phosphoinositide-3-kinases (PI3K)/PI3K-protein kinase B (Akt), and myosin light
chain kinase (MLCK)- myosin light chain (MLC20), were analyzed using immunoblotting. Serum amino acids analysis showed
that DSS treatment changed the serum contents of amino acids, such as Trp, Glu, and Gln (P,0.05). Dietary arginine or
glutamine supplementation had significant (P,0.05) influence on the clinical and biochemical parameters (T-SOD, IL-17 and
TNF-a) in colitis model. These results were associated with colonic NF-kB, PI3K-Akt and MLCK signaling pathways. In
conclusion, arginine or glutamine could be a potential therapy for intestinal inflammatory diseases.
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Introduction
Inflammatory bowel diseases (IBD), including ulcerative colitis
(UC) and Crohn’s disease, are chronic gastrointestinal disorders
characterized by chronic intestinal inflammation. The pathogen-
esis of IBD remains unclear, but imbalance between pro-
inflammatory mediators, i.e. reactive oxygen mediators and
cytokines, and anti-inflammatory responses is considered to be a
key factor in the development and perpetuation of IBD [1].
Although the understanding of the pathogenesis in IBD is
progressing, new therapeutic strategies continue to be investigated.
Nutrients, capable of control the pro-inflammation, are shown to
be beneficial in spontaneous and induced colitis models [2]. For
example, vitamin D provides significantly beneficial role in IBD
via mediating the expressions of target genes, including pro-
inflammatory cytokines [3–5]. Besides that, compelling investiga-
tions have indicated that arginine or glutamine might be a good
candidate for IBD treatment with low risk [6,7]. For instance,
post-treatment with alanyl-glutamine attenuates inflammatory
response in dextran sulfate sodium (DSS)-induced colitis by
suppressing Th17-associated cytokine expressions, reducing mac-
rophage infiltration into the peritoneal cavity, and decreasing pro-
inflammatory cytokine production in the colon [8]. Meanwhile,
arginine supplementation improves the clinical parameters,
including mortality, body weight and colon weight, and lowers
the colonic permeability and the number of myeloperoxidase-
positive neutrophils in colitis induced by DSS [9]. These well-
designed investigations have indicated that these amino acids
supplementation could be a potential therapy for IBD.
However, before recommending its use in clinical application, it
is important to elucidate several important points. Firstly, it is
necessary to analyze the serum profile of amino acids in the
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process of colonic injury and the recovery from IBD. Meanwhile,
it is fruitful to investigate the suitable time, dose and means of
arginine or glutamine supplementation to optimize its functions in
IBD. Additionally, the biological mechanism of glutamine or
arginine supplementation for IBD needs further elucidation. Thus,
in the current study, we firstly determined the serum profile of
amino acids in DSS-induced colitis in mice. Then, the impact of
graded dose of arginine or glutamine supplementation on murine
colitis caused by DSS was studied. The measured variables include
serum amino acids, clinical parameters, antioxidative indicators
[catalase, total superoxide dismutase (T-SOD), glutathione per-
oxidase (GSH-Px)], tight junction proteins [occludin, claudin-1,
zonula occludens-1(ZO-1)], pro-inflammatory cytokines [interleu-
kin-1 beta (IL-1b), IL-6, IL-17 and tumor necrosis factor alpha
(TNF-a)] and signaling pathways [nuclear factor kappa B (NF-kB),
mitogen-activated protein kinases (MAPK), phosphoinositide-3-
kinases(PI3K)/PI3K-protein kinase B (Akt), myosin light chain
kinase (MLCK)- myosin light chain (MLC20)].
Materials and Methods
Antibodies
Antibodies specific against occludin, claudin-1, zonula occlu-
dens-1 (ZO1), myosin light chain kinase (MLCK), myosin light
chain (MLC20), p85, p-Akt, JNK and p-JNK were purchased
from Santa Cruz Biotechnology, Inc.(Dallas, Texas, USA).
Antibodies against ERK1/2, p-ERK1/2, p-38, p-p-38, p-65 were
purchased from Cell Signaling Technology (Danvers, MA, USA).
Experiment design
400 female ICR (Institute for Cancer Research) mice (6-week-
old) were purchased from SLAC Laboratory Animal Central
(Shanghai, China). The mice were housed in a pathogen-free
mouse colony (temperature, 20–30uC; relative humidity, 45–60%;
lighting cycle, 12 h/d) and had free access to food and drinking
water. Animals were randomly divided into eight groups: 1) all
mice were treated with distilled water and basal diet (NC) (n = 80);
2) all mice were treated with basal diet and distilled water
containing 5% (wt/vol) DSS (MW 5000, KAYON Bio. Techology
Co. Ltd) for 7 days (DS) (n = 80); 3) all mice were treated with DSS
and dietary 0.5% glutamine (Ajinomoto Inc., Tokyo, Japan)
supplementation (0.5-GS) (n = 40); 4) all mice were treated with
DSS and dietary 1.0% glutamine supplementation (1.0-GS)
(n = 40); 5) all mice were treated with DSS and dietary 2.0%
glutamine supplementation (2.0-GS) (n = 40); 6) all mice were
treated with DSS and dietary 0.4% arginine (Ajinomoto Inc.,
Tokyo, Japan) supplementation (0.4-AS) (n = 40); 7) all mice were
treated with DSS and dietary 0.8% arginine supplementation (0.8-
AS) (n = 40); 8) all mice were treated with DSS and dietary 1.5%
arginine supplementation (1.5-AS) (n = 40). In arginine or
glutamine supplementation groups, mice received arginine or
glutamine from same day treating with DSS (day 1) to 5 days post
DSS treatment (day 12). 20 mice from NC and DS groups were
killed at day 3, 7, 10 and 12 to collect serum and colon for further
analyses. Meanwhile, 20 mice in different dose of arginine or
glutamine supplementation groups were killed at day 7 and 12 for
serum and colon collection. Moreover, body weights were
recorded daily during the experimental period, and the length
and weight of colon were measured during the sample collection.
After experiment, disease activity index (DAI) scores were
analyzed to assess the severity of colitis. The scoring system was
based on body weight gain, colon length, colon weight, and
colonic inflammatory score via histological evaluation [10,11].
This study was performed according to the guidelines of the
Laboratory Animal Ethical Commission of the Chinese Academy
of Sciences, and approved by Laboratory Animal Ethical
Commission of the Institute of Subtropical Agriculture, Chinese
Academy of Sciences (0207).
Serum amino acid analysis
Before slaughter, six blood samples in each group at each time
point were collected with orbital blooding. Then serum was
separated with centrifugation at 3,5006g for 15 min at 4uC and
stored at 220uC. Serum amino acids were analyzed with isotope
dilution liquid chromatography-mass spectrometry methods by
Beijing Amino Medical Research CO., LTD, Beijing, China.
Real-time quantitative (RT-PCR)
Total RNA was isolated from liquid nitrogen frozen and ground
colon with TRIZOL regent (Invitrogen, USA) and then treated
with DNase I (Invitrogen, USA) according to the manufacturer’s
instructions. Synthesis of cDNA was performed with oligo (dT) 20
and Superscript II reverse transcriptase (Invitrogen, USA).
Primers (Table 1) were designed with Primer 5.0 according to
mouse gene sequence. b-actin was used as an internal control to
normalize target gene transcript levels. Real-time PCR was
performed according to our previous study [12]. Briefly, 1 ml
cDNA template was added to a total volume of 10 ml containing
5 ml SYBR Green mix, 0.2 ml Rox, 3 ml ddH2O, and 0.4 ml each
Table 1. Primers used in this study.
Gene ID Nucleotide sequence of primers (59–39) Product Length Ref.
b-actin NM_007393.3 F:GTCCACCTTCCAGCAGATGT
R:GAAAGGGTGTAAAACGCAGC
117 [38]
IL-1b NM_008361.3 F:ATGAAAGACGGCACACCCAC
R:GCTTGTGCTCTGCTTGTGAG
175 This study
IL-6 NM_031168.1 F:TGCAAGAGACTTCCATCCAGT
R:GTGAAGTAGGGAAGGCCG
71 This study
IL-17 NM_010552.3 F:TACCTCAACCGTTCCACGTC
R:TTTCCCTCCGCATTGACAC
119 This study
IL-18 NM_008360.1 F:AGACAACTTTGGCCGACTTC
R:CCTTCACAGAGAGGGTCACA
203 This study
TNF-a NM_013693.2 F:AGGCACTCCCCCAAAAGAT
R:TGAGGGTCTGGGCCATAGAA
192 This study
doi:10.1371/journal.pone.0088335.t001
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of forward and reverse primers. We used the following protocol: (i)
pre-denaturation program (10 s at 95uC); (ii) amplification and
quantification program, repeated 40 cycles (5 s at 95uC, 20 s at
60uC); (iii) melting curve program (60–99uC with a heating rate of
0.1uC/s and fluorescence measurement). The relative expression
was expressed as a ratio of the target gene to the control gene using
the formula 2-(DDCt), where DDCt= (CtTarget - Ctb-actin)treat-
ment - (CtTarget - Ctb-actin)control. Relative expression was
normalized and expressed as a ratio to the expression in the
control group.
Immunoblotting
Western blot analysis was conducted according to a previous
study [13]. Briefly, the equal amounts of proteins obtained from
cytoplasmic or nuclear fractions were separated by a reducing
SDS-PAGE electrophoresis. The proteins were transferred onto
PVDF membranes (Millipore, MA, USA) and blocked with 5%
non-fat milk in Tris-Tween buffered saline buffer (20 mM Tris,
pH 7.5,150 mM NaCl, and 0.1% Tween-20) for 3 hr. The
primary antibodies were incubated overnight at 4uC; the HRP-
conjugated secondary antibodies were subsequently incubated for
1 hr at room temperature before developing the blots using Alpha
Imager 2200 software (Alpha Innotech Corporation, CA, USA).
We digitally quantified the resultant signals and normalized the
data to the proliferating cell nuclear antigen (PCNA) or actin
abundance. PCNA or actin was used as an internal loading control
for nuclear and cytoplasmic protein fractions, respectively.
Catalase,T-SOD and GSH-Px activity analysis
The whole colon tissue was sampled from each mouse and
homogenized (1 g/10 ml physiological saline solution) on ice. The
homogenized solution centrifuged at 3,5006g for 15 min at 4uC,
and the resultant liquid supernatant stored at 220uC. Catalase,
total superoxide dismutase (T-SOD) activity and glutathione
peroxidase (GSH-Px) in the colon were measured using spectro-
photometric kits in accordance with the manufacturer’s instruc-
tions (Nanjing Jiangcheng Biotechnology Institute, China)
Morphological analyses
For light microscopic observation, the colon tissues were fixed
with 10% formalin in PBS at 4uC, dehydrated in a graded series of
ethanol, and then embedded in paraffin wax. The tissues were
sectioned at 5 mm thick and mounted on slides. They were
dewaxed, hydrated, and then stained with Hematoxylin-Eosin.
Immunohistochemistry analyses
Tissues obtained from the colon of mice were fixed in 10%
buffered formalin for 24 hr at room temperature and embedded in
paraffin. The evaluations of occludin, ZO-1 and claudin-1 were
made on 3 mm paraffin embedded slides, the sections were
dewaxed in xylene, rehydrated in an ascendent ethanol scale and
pre-treated in a microwave oven (two cycles for 5 minutes each at
780 W, in EDTA buffer, pH 8.0). Endogen biotin and non-
specific signals were blocked with appropriated reagents. For
immunohistochemistry, the treated slides were incubated with
primary antibodies for 2 hr at room temperature in a humid
chamber, washed in PBS, and visualized by biotinylated secondary
antibodies followed by incubation with HRP-Conjugated Strepta-
vidin for 30 min (R&D Systems, London, UK). The chromogen
was 3, 39-diaminobenzidine free base (DAB).
Statistical analysis
Data were expressed as means6 the standard error of the mean
(SEM). All statistical analyses were performed using the SPSS 16.0
software (Chicago, IL, USA). Data were analyzed between NC
and DS groups by the Student’s t-test, while among NC, DS, AS
and GS groups by the One-Way ANOVA method. Differences
with P,0.05 were considered significant.
Results
Serum amino acids profile after DSS treatment
DSS induced colitis was used as a murine colonic injury and
repair model for its similarities to human UC. The serum profile of
amino acids was detected at day 3, 7, 10 and 12. At day 3, DSS
significantly (P,0.05) decreased serum levels of Trp (tryptophane)
and Aad (a-aminoadopic acid), while remarkably (P,0.05)
promoted serum levels of bAib (b-aminoisobutyric acid), bAla
(b-alanine) and Gln (glutamine), and had little effect on serum
Table 2. Serum amino acids profile in DSS treated group and
control group.
D3 D7 D10 D12
Trp
Control 26.8762.89a 19.6961.32a 22.4561.57 19.0761.52
DS 13.9360.95b 13.4360.69b 19.0662.15 14.7261.15
bAib
Control 0.1860.01b 0.4760.02 0.4860.03 0.5160.02b
DS 0.2560.01a 0.5060.01 0.4560.01 0.6760.02a
GABA
Control 0.2060.03 0.3660.60a 0.0960.01 0.1460.03
DS 0.3060.01 0.2360.08b 0.1260.03 0.1760.04
Aad
Control 1.1860.28a 0.8360.13 0.6060.06 0.4860.04
DS 0.6360.04b 0.8760.12 0.6260.07 0.4260.05
1MHis
Control 0.8660.09 1.0660.03a 1.0160.07 1.1360.06
DS 0.8760.03 0.8160.06b 1.0260.08 1.0660.06
Glu
Control 36.6963.63 41.3262.02a 35.3762.71 43.2763.55
DS 37.0961.64 31.8862.76b 37.0662.87 36.4061.43
bAla
Control 1.0360.04b 0.8960.04b 0.7660.08 0.7260.02b
DS 1.35460.06a 1.0360.02a 0.6560.04 0.8960.04a
Asp
Control 4.6560.65 7.7160.39a 4.8560.44 6.9760.63
DS 4.5660.48 4.4060.60b 4.6060.43 7.5860.76
Gln
Control 60.9564.06b 41.1762.26 57.1162.90a 62.5066.87a
DS 82.6863.86a 57.0565.72 43.7763.47b 45.5364.53b
PEtN
Control 1.5860.15 1.3260.19 1.9860.13b 2.0960.33
DS 1.9860.10 0.8060.09 2.8960.18a 1.9560.26
Arginine availability index (AAI) = serum [L-Arg]/([L-Orn] + [L-Lys])
Control 0.4260.04 0.3660.02 0.4260.03 0.4960.03a
DS 0.4060.02 0.3860.02 0.4760.05 0.3560.04b
Mice were treated with DSS (DS) or normal drinking (Control). Data are
presented as mean 6 SEM, n= 6, with a-b used to indicate a statistically
significant difference from control (P,0.05, Student’s t- test).
doi:10.1371/journal.pone.0088335.t002
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profile of other amino acids (Table 2 and Table S1). At day 7, DSS
treatment significantly decreased (P,0.05) serum levels of Trp,
GABA (c-amino-n-butyric acid), 1MHis (1-methyl-L-histidine),
Glu (glutamic acid) and Asp (Aspartic acid), while increased the
serum level of bAla (beta-alanine), and had little effect on serum
levels of other amino acids (Table 2 and Table S1). No significant
difference was found about serum profile of amino acids between
control and DS groups at day 10 and 12, except that serum level of
Gln significantly (P,0.05) lowered in DS group at day 10 and 12
(Table 2 and Table S1). Meanwhile, arginine availability index
(AAI) in DS group was significant (P,0.05) lower than that in NC
group at day 12, while had no significant difference at day 3, 7 and
10 (Table 2).
Figure 1. Arginine or glutamine supplementation affects the clinic parameters in dextran sulfate sodium colitis. A: Body weight was
calculated in each group. B: Colon weight was measured in control and DS groups at day 7, 10 and 12. C: Colon weight was measured in each group
at day 7. D: Colon weight was measured in each group at day 12. E: Colon length was collected in each group at day 7. F: Colon length was collected
in each group at day 12. G: Disease activity score was calculated in each group at day 7. H: Disease activity score was calculated in each group at day
12. I: Colon length was measured in control and DS groups at day 7, 10 and 12. J: Colonic morphological analyses with Hematoxylin-Eosin staining in
each group at day 7. K: Colonic morphological analyses with Hematoxylin-Eosin staining in each group at day 12. Mice were treated with normal
drinking (control), or distilled water containing 5% (wt/vol) dextran sulfate sodium (DS), or dextran sulfate sodium water with different dose of
arginine supplementation in diet (DS+ Arg), or dextran sulfate sodium water with different dose of glutamine supplementation in diet (DS+ Gln). Data
are presented as mean 6 SEM, n= 6, with a-c used to indicate a statistically significant difference (P,0.05, one way ANOVA method).
doi:10.1371/journal.pone.0088335.g001
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Table 3. Serum amino acids profile with arginine or
glutamine supplementation in DSS-induced colitis model.
D7 D12
Trp
DS 13.4360.69a 14.7261.15a
DS+Arg 6.8760.50b 8.2260.57b
DS+Gln 7.1160.72b 8.1060.44b
Phe
DS 17.5061.04a 14.0560.62b
DS+Arg 12.6260.42b 16.2061.61ab
DS+Gln 11.6161.10b 17.7860.97a
Leu
DS 30.4662.27a 20.5761.52b
DS+Arg 25.6061.66ab 27.7363.36ab
DS+Gln 22.7262.99b 34.2861.51a
Ile
DS 19.4361.48a 13.1460.75
DS+Arg 13.2461.33b 15.8762.43
DS+Gln 10.7261.28b 16.3361.09
Tyr
DS 20.5361.99 22.0961.71
DS+Arg 19.6361.73 21.7263.20
DS+Gln 21.1262.29 26.1761.88
Val
DS 44.7863.72a 29.3762.32
DS+Arg 24.1460.62b 33.0365.69
DS+Gln 21.2062.82b 35.0462.56
Met
DS 40.7364.48a 23.7362.93b
DS+Arg 23.3661.02b 40.1269.03ab
DS+Gln 30.0565.96ab 41.0265.32a
Lys
DS 113.7266.40a 88.6665.44a
DS+Arg 44.4762.82b 55.1167.68b
DS+Gln 44.2765.33b 65.1765.37b
Orn
DS 27.0861.96ab 20.0161.95b
DS+Arg 32.9563.42a 29.1665.41a
DS+Gln 24.5662.96b 31.7762.92a
Pro
DS 25.9961.80a 21.3361.43
DS+Arg 16.4561.55b 24.9865.41
DS+Gln 18.6861.88b 21.6361.17
Abu
DS 0.6160.42b 0.6360.06b
DS+Arg 3.9561.05a 3.5260.43a
DS+Gln 4.9461.47a 2.9760.43a
Arg
DS 54.6264.52a 43.3262.93b
DS+Arg 39.1662.38b 47.8962.84b
DS+Gln 35.5262.46b 62.0965.76a
Table 3. Cont.
D7 D12
3MHis
DS 0.5260.04b 0.4460.03b
DS+Arg 0.7460.08a 0.7460.05a
DS+Gln 0.8760.07a 0.9460.06a
1MHis
DS 0.8160.06a 1.0660.06a
DS+Arg 0.7660.06ab 0.8560.05b
DS+Gln 0.5760.07b 1.0160.06ab
Glu
DS 31.8862.76 36.4061.43
DS+Arg 27.0361.60 32.5762.10
DS+Gln 29.6162.89 34.1661.92
Ala
DS 54.0363.17 48.1761.96
DS+Arg 54.5464.89 54.2568.67
DS+Gln 60.4965.60 67.2364.90
Cit
DS 28.8361.96a 21.2860.67
DS+Arg 17.5361.19b 19.8862.32
DS+Gln 17.4262.04b 23.7962.94
Thr
DS 54.6762.88a 36.2963.23a
DS+Arg 20.5161.35b 25.9663.97b
DS+Gln 23.8264.56b 25.3063.88b
His
DS 23.8662.02c 18.1061.98b
DS+Arg 51.6763.89a 49.2164.73a
DS+Gln 40.6066.49b 50.0765.28a
Asp
DS 4.4060.60 7.5860.76a
DS+Arg 3.4360.34 4.6160.65b
DS+Gln 3.6660.69 4.6060.49b
Gln
DS 57.0565.72 45.5364.53b
DS+Arg 65.8665.03 87.5268.27a
DS+Gln 61.0363.26 88.48611.77a
Gly
DS 33.6361.57b 28.9361.05b
DS+Arg 31.2162.06b 27.9964.05b
DS+Gln 58.1363.72a 36.7763.75a
Hyp
DS 3.9660.31b 3.3160.15b
DS+Arg 12.8860.98a 12.2461.29a
DS+Gln 13.9461.22a 12.5260.96a
Ser
DS 28.6761.15b 25.8661.88
DS+Arg 30.5763.67b 30.8063.36
DS+Gln 39.3263.21a 30.2463.36
Asn
DS 9.6360.76 7.2460.30b
Amino Acids and Colitis
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Average weight gain, colon length, and DAI scores after
DSS treatment
Previous study reported that DSS causes weight loss in mice [8].
Thus, this study also calculated the average weight gain (AWG)
from day 1 to 12. No significant difference was found between two
groups at this period (Figure 1A). However, the results indicated
that DSS significantly (P,0.05) lowered the daily weight gain at
day 7, compared to normal mice (21.060.10 vs. 20.1260.09).
Meanwhile, DSS significantly (P,0.05) shortened colon length at
day 7, 10 and 12 (Figure 1I), and increased colon weight at day 7
(Figure 1B), compared to those in NC group. Moreover, compared
with NC group, there was a marked neutrophilic infiltration after
exposure to DSS at day 7 and 12 (Figure 1 J and K). Based on
these data, we analyzed the DAI score in colon after DSS
treatment. As shown in figure 1G and H, mouse in DS group
exhibited a higher (P,0.05) DAI score compared with that in
control group at day 7 and 12, respectively.
Table 3. Cont.
D7 D12
DS+Arg 8.8460.65 10.2061.03a
DS+Gln 9.3261.04 9.1860.98ab
Arginine availability index (AAI) = serum [L-Arg]/([L-Orn] + [L-Lys])
DS 0.3860.02b 0.3560.04b
DS+Arg 0.5260.03a 0.6460.06a
DS+Gln 0.5760.05a 0.5960.03a
At day 7, serum amino acids profile in mice treated with DSS feeding basal diet
(DS), or 1.5% arginine supplementation (DS+Arg), or 2.0% arginine
supplementation (DS+Gln), were detected. At day 12, serum amino acids profile
in mice treated with DSS feeding basal diet (DS), or 0.4% arginine
supplementation (DS+Arg), or 0.5% glutamine supplementation at day 12
(DS+Gln), were detected. Data are presented as mean 6SEM, n= 6, with a-c
used to indicate a statistically significant difference (P,0.05, one way ANOVA
method).
doi:10.1371/journal.pone.0088335.t003
Figure 2. Antioxidant enzymes activities in each group. A: SOD activity in each group. B: Catalase activity in each group. C: GSH-Px activity in
each group. Mice were treated with normal drinking (control), or distilled water containing 5% (wt/vol) dextran sulfate sodium (DS), or dextran sulfate
sodium water with dietary 0.4% arginine supplementation (DSS+0.4% Arg), or dextran sulfate sodium water with dietary 0.5% glutamine
supplementation (DS+ 0.5% Gln). Data are presented as mean6 SEM, n=6, with a-c used to indicate a statistically significant difference (P,0.05, one
way ANOVA method). T-SOD: total superoxide dismutase, GSH-Px: glutathione peroxidase.
doi:10.1371/journal.pone.0088335.g002
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Average weight gain and colon length after amino acids
supplementation
Firstly, we calculated the average weight gain and colonic
parameters with graded dose of arginine or glutamine supple-
mentation in mouse model with DSS-induced colitis to explore the
effects of glutamine or arginine supplementation on IBD. About
weight gain, no significant difference was found among graded
dose of arginine or glutamine supplementation (Figure 1A). For
colon weight, graded dose of arginine supplementation had little
effect on colon weight at day 7 and 12 (Figure 1 C and D).
However, dietary 2.0% glutamine supplementation significantly
(P,0.05) decreased the colon weight at day 7, compared to that in
DS group (Figure 1C). For colon length, at day 7, dietary 1.5%
arginine supplementation significantly (P,0.05) increased the
colon length, while other dose of arginine supplementation had
little effect on colon length, compared to those at DS (Figure 1E).
Glutamine supplementation had little effect on colon length
compared to those in DS (Figure 1E). At day 12, colon length in
0.8-AS, or 1.5-AS, or 0.5-GS group was significant (P,0.05)
longer than those in DS group (Figure 1F). Collectively, It seems
that higher dose of glutamine (2.0%) or arginine (1.5%)
supplementation is better than lower one in mouse model with
DSS-induced colitis at first week, while lower dose of glutamine
(0.5%) or arginine (0.4%) supplementation is appropriate at
recover period from DSS-induced colitis. Indeed, HE staining also
demonstrated that arginine or glutamine supplementation remark-
ably alleviated neutrophilic infiltration in the colon at day 7
Table 4. Pro-inflammatory cytokines expression with arginine
or glutamine supplementation in DSS-induced colitis model.
IL-1b IL-6 IL-17 TNF-a
D 7
DS 1.0060.02b 1.0060.02 1.0060.03c 1.0060.02b
DS+Arg 1.0660.02b 1.0060.02 1.1260.02b 1.3560.03a
DS+Gln 1.1460.03a 1.0160.02 1.2460.02a 1.2760.06a
D 12
DS 1.0060.01 1.0060.01 1.0060.01a 1.0060.03b
DS+Arg 1.0260.02 1.0260.03 0.8660.02b 0.8660.02c
DS+Gln 1.0060.02 1.0160.02 1.2060.02a 1.1860.03a
At day 7, colonic proinflammatory cytokines production in mice treated with
DSS feeding basal diet (DS), or 1.5% arginine supplementation (DS+Arg), or
2.0% arginine supplementation (DS+Gln), were detected. At day 12, colonic
proinflammatory cytokines production in mice treated with DSS feeding basal
diet (DS), or 0.4% arginine supplementation (DS+Arg), or 0.5% glutamine
supplementation at day 12 (DS+Gln), were detected. Data are presented as
mean 6SEM, n= 6, with a-c used to indicate a statistically significant difference
(P,0.05, one way ANOVA method). IL: Interleukin, TNF: tumor necrosis factor.
doi:10.1371/journal.pone.0088335.t004
Figure 3. Activation of p38 in colon. A: Immunoblotting of total and phosphorylated p38 at day 7. B: The ratio of phosphorylated p38 to total
p38 from data shown in A. C: Immunoblotting of total and phosphorylated p38 at day 12. D: The ratio of phosphorylated p38 to total p38 from data
shown in C. Mice were treated with normal drinking (control), or distilled water containing dextran sulfate sodium (DS), or dextran sulfate sodium
water with dietary 0.4% arginine supplementation (DSS+0.4% Arg), or dextran sulfate sodium water with dietary 1.5% arginine supplementation
(DSS+1.5% Arg), or dextran sulfate sodium water with dietary 0.5% glutamine supplementation (DS+ 0.5% Gln), or dextran sulfate sodium water with
dietary 2.0% glutamine supplementation (DS+ 2.0% Gln). Data are presented as mean 6SEM, n=5.
doi:10.1371/journal.pone.0088335.g003
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(higher dose of supplementation, Figure 1J) and 12 (lower dose of
supplementation, Figure 1K). However, arginine or glutamine
supplementation failed to significantly decrease the DAI at day 7
and 12 (Figure 1J and K).
Serum amino acids profile after amino acids
supplementation
To monitor the effect of glutamine or arginine supplementation
on serum profile of amino acids in mouse colitis induced by DSS,
we determined the serum profile of amino acids in DS, 2.0-GS and
1.5-AS groups at day 7, and in DS, 0.5-GS, and 0.4-AS groups at
day 12. As shown in table 3, arginine supplementation significantly
(P,0.05) decreased serum levels of various amino acids, including
Trp, Phe (phenylalanine), Ile (isoleucine), Val (valine), Met
(methionine), Lys (lysine), Pro (proline), Arg, Cit (citrulline) and
Thr (threonine), while remarkably (P,0.05) increased serum levels
of Abu (a-amino-n-butyric acid), 3MHis (3-methyl-L-histidine),
His (histidine) and Hyp (hydroxy-L-proline), compared to those in
DS group at day 7. Meanwhile, dietary glutamine supplementa-
tion also significantly (P,0.05) decreased serum levels of various
amino acids, compared with those in DS group (Table 3). These
amino acids include Trp, Phe, Leu, Ile, Val, Lys, Orn (ornithine),
Pro, Arg, 1MHis, Cit and Thr. At same time, glutamine
supplementation obviously (P,0.05) enhanced serum levels of
Ser (serine), Hyp, Gly, His, 3MHis and Abu (Table 3). At day 12,
serum levels of several amino acids, including His, Gln, Hyp, Lys,
Orn, Abu, Arg, Asn (asparagine) and 3MHis, were much higher
(P,0.05) in 0.4-AS group than those in DS group (Table 3).
Meanwhile, arginine supplementation also significantly (P,0.05)
decreased serum levels of Trp, 1MHis, Asp and Thr, compared
with those in DS group at day 12 (Table 3). Glutamine
supplementation significantly (P,0.05) increased serum profiles
of various serum amino acids, including Phe, Leu (leucine), Met,
Lys, Orn, Abu, Arg, 3MHis, His, Gln. Gly and Hyp, compared
with those in DS group at day 12 (Table 3). Besides that,
glutamine supplementation also remarkably (P,0.05) decreased
serum levels of Trp, Thr and Asp, compared with those in DS
group at day 12 (Table 3). Furthermore, arginine or glutamine
supplementation significantly (P,0.05) increased AAI at day 7 and
12, compared to the DS group (Table 3).
Catalase, T-SOD and GSH-Px activity
Oxidative stress has been involved in the pathogenesis of
inflammatory bowel disease, and investigations have found that
the inflamed mucosa increases the production of reactive oxygen
metabolities, such as superoxide, hydroxyl radical and hydrogen
peroxide [14]. Thus, we detected some factors in anti-oxidative
system, including catalase, T-SOD and GSH-Px. No significant
difference was found between NC and DS group, or between DS
and 0.4-AS or 0.5-GS groups about catalase (Figure 2 B) and
GSH-Px (Figure 2 C) at day 12. However, DSS treatment
significantly (P,0.05) decreased T-SOD activity in the colon,
compared to those in NC group (Figure 2 A). Arginine
supplementation significantly (P,0.05) reversed the decrease of
T-SOD caused by DSS, while glutamine supplementation had
Figure 4. Activation of JNK in colon. A: Immunoblotting of total and phosphorylated JNK at day 7. B: Immunoblotting of total and
phosphorylated JNK at day 12. C: The ratio of phosphorylated JNK to total JNK from data shown in A. D: The ratio of phosphorylated JNK to total JNK
from data shown in B. Mice were treated with normal drinking (control), or distilled water containing dextran sulfate sodium (DS), or dextran sulfate
sodium water with dietary 0.4% arginine supplementation (DSS+0.4% Arg), or dextran sulfate sodium water with dietary 1.5% arginine
supplementation (DSS+1.5% Arg), or dextran sulfate sodium water with dietary 0.5% glutamine supplementation (DS+ 0.5% Gln), or dextran sulfate
sodium water with dietary 2.0% glutamine supplementation (DS+ 2.0% Gln). Data are presented as mean 6SEM, n=5. JNK: c-Jun N-terminal kinase.
doi:10.1371/journal.pone.0088335.g004
Amino Acids and Colitis
PLOS ONE | www.plosone.org 8 February 2014 | Volume 9 | Issue 2 | e88335
little effect on T-SOD activity, compared to those in DS group
(Figure 2 A).
Pro-inflammatory cytokines in colon
An increased production of proinflammatory cytokines [TNF-a,
IL-1b, IL-6, IL-17] has been reported in patients with IBD. In this
study, we found that arginine supplementation significantly
(P,0.05) promoted the colonic expressions of IL-17 and TNF-a
at day 7, compared to those in DS group (Table 4). At day 12,
arginine supplementation significantly (P,0.05) reduced the
expressions of IL-17 and TNF-a in the colon (Table 4). Also,
glutamine supplementation remarkably (P,0.05) promoted the
colonic expressions of TNF-a, IL-1b and IL-17 at day 7, and
expression of TNF-a at day 12, compared to the DS group
(Table 4).
MAPK and NF-kB pathway
The activation of MAPK and NF-kB pathways has been
implicated in the pathogenesis of IBD [15]. Dietary arginine or
glutamine supplementation had little effect on the activation of
p38 and JNK pathway in the colon at day 7 and 12 (Figure 3 and
4). About NF-kB pathway, dietary glutamine supplementation
significantly (P,0.05) inhibited the activation of colonic nuclear
p65 at day 7, while had little effect on p65 abundance at day 12,
compared to DS group (Figure 5). Arginine supplementation had
little effect on the colonic nuclear p65 abundance at day 7 and 12,
compared to DS group (Figure 5).
PI3K-Akt and MLCK-MLC20 pathway
PI3K-Akt pathway may be an important factor in maintenance
of inflammation and tissue damage in IBD because it is responsible
for the migration of leukocytes from the bloodstream to sites of
injury or infection [16]. At day 7, arginine supplementation
significantly (P,0.05) increased the abundance of colonic PI3K,
while glutamine supplementation had little effect on colonic PI3K-
Akt pathway, compared to those in DS group (Figure 6). However,
dietary arginine or glutamine supplementation significantly
(P,0.05) inhibited the activation of colonic PI3K-Akt pathway
at day 12, compared to the DS group (Figure 6).
MLCK-MLC20 pathway also plays an important role on IBD
because this pathway involves in tight junction dysregulation and
epithelial damage, resulting in barrier loss in patients with IBD.
Figure 5. Abundance of p65 in the colon. A: Immunoblotting of colonic nuclear p65 at day 7. B: Immunoblotting of colonic nuclear p65 at day
12. C: Quantification of relative colonic nuclear p65 abundance from data shown in A. D: Quantification of relative colonic nuclear p65 abundance
from data shown in B. Mice were treated with normal drinking (control), or distilled water containing dextran sulfate sodium (DS), or dextran sulfate
sodium water with dietary 0.4% arginine supplementation (DSS+0.4% Arg), or dextran sulfate sodium water with dietary 1.5% arginine
supplementation (DSS+1.5% Arg), or dextran sulfate sodium water with dietary 0.5% glutamine supplementation (DS+ 0.5% Gln), or dextran sulfate
sodium water with dietary 2.0% glutamine supplementation (DS+ 2.0% Gln). Data are presented as mean 6SEM, n= 5, with a-b used to indicate a
statistically significant difference (P,0.05, one way ANOVA method). PCNA: proliferating cell nuclear antigen.
doi:10.1371/journal.pone.0088335.g005
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Glutamine supplementation had little effect on this pathway at
colon at day 7 and 12, compared to the DS group (Figure 7).
Arginine supplementation significantly (P,0.05) decreased colonic
MLCK abundance at day 12, while it had little effect on this
pathway at day 7, compared with those in DS group (Figure 7).
Expression of tight junction
Tight junctions, the first physical barrier against a variety of
pathogens, act as a main mechanism to maintain the homeostasis
in gastrointestinal tract. We, hence, quantified the expressions of
tight junctions (claudin1, occludin, and ZO1) via immunohisto-
chemistry analyses. As shown in Figure 8, the expression of
claudin-1 exhibited little difference between the control and DS
group, while dietary supplementation with arginine and glutamine
obviously enhanced its abundance at day 7 (Figure 8). At day 12,
the expression of claudin-1 significantly decreased at DS group
and amino acid groups compared with that at control group
(Figure 8). However, we failed to notice a similar trend in the
expressions of occludin (Figure 8) and ZO-1 (Figure 8).
Discussion
Numerous compelling investigations have indicated that a
metabolic alteration will occur in patients with IBD, resulting in
the change of serum profile of amino acids. For example, one well-
designed study has found that several serum amino acids, such as
isoleucine and lysine, show a strong increase in patients with UC
[17]. Similarly, another investigation has showed that plasma His
concentrations in both CD and UC patients are significantly lower
than the health patients [18]. Also, serum concentrations of L-Arg,
L-Lys, L-Orn, L-Pro, and L-Cit increase in the mice treated with
DSS, compared to untreated control mice [9]. However, in
contrast to previous reports, we found that serum levels of Trp,
Glu, Gln and AAI decrease in the mice treated with DSS. Besides
that, no much difference is found between DSS treated and
Figure 6. Activation of colonic PI3K-Akt pathway. A: Immunoblotting of colonic PI3K and p-Akt at day 7. B: Quantification of relative PI3K
abundance from data shown in A. C: Quantification of relative P-Akt abundance from data shown in A. D: Immunoblotting of colonic PI3K and p-Akt
at day 12. E: Quantification of relative PI3K abundance from data shown in D. F: Quantification of relative P-Akt abundance from data shown in E. Mice
were treated with normal drinking (control), or distilled water containing dextran sulfate sodium (DS), or dextran sulfate sodium water with dietary
0.4% arginine supplementation (DSS+0.4% Arg), or dextran sulfate sodium water with dietary 1.5% arginine supplementation (DSS+1.5% Arg), or
dextran sulfate sodium water with dietary 0.5% glutamine supplementation (DS+ 0.5% Gln), or dextran sulfate sodium water with dietary 2.0%
glutamine supplementation (DS+ 2.0% Gln). Data are presented as mean 6SEM, n=5, with a-b used to indicate a statistically significant difference
(P,0.05, one way ANOVA method). PI3K: Phosphatidylinositide 3-kinases, Akt: protein kinases B.
doi:10.1371/journal.pone.0088335.g006
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control mice. The rationale for this discrepancy remains unknown;
perhaps it is related to different samples detected or the sensitivity
of diverse detection methods. Indeed, similar to our discovery,
other study has suggested that plasma concentration of Trp
significantly decreases in IBD patients, and this decrease inversely
correlates with disease activity [18]. Similarly, another study has
also indicated that levels of glutamic acid and glutamine
significantly decrease in the acute phase of colonic inflammation
[19]. The underling biological mechanism for the decrease of Trp,
Glu, Gln levels and AAI in DSS-induced colitis merits further
investigation. To our knowledge, this is the first time to determine
serum profile of amino acids in the progress of colitis and its
recover in the mice explored to DSS. Our discovery may provide
metabolic evidence for the beneficial functions of Arg, Glu and
Gln supplementation in IBD patients. Furthermore, amino acids
profiles in tissue or urine still need further investigate in the
progress of IBD and its recovery.
Previous studies have indicated that DSS induces acute colitis
and increases DAI score in ICR mice [20–22], we also found DSS
treatment causes significant colonic damages to mice. Dietary
arginine or glutamine supplementation obviously alleviates the
damages caused by DSS. Indeed, increasing studies have
demonstrated that arginine or glutamine supplementation is
beneficial for decrease the weight loss or colonic damages in mice
caused by DSS [9,23,24]. Interestingly, the beneficial function of
arginine or glutamine supplementation in IBD depends on the
supplemental dosage, which also differs from different period of
the disease. Similarly, our previous study has indicated that the
effect of glutamine supplementation on the burden of Pasteurella
multocida and the expressions of its major virulence factors in mice
is also dose and tissue dependent [25]. The exact mechanism may
relate to the metabolism and balance of amino acids. To our
knowledge, this is first study to investigate the effect of graded dose
of arginine or glutamine supplementation on the pathogenesis of
IBD. However, the optimal supplementation time for arginine or
glutamine in IBD still needs further investigation. Metabolically,
arginine or glutamine supplementation causes remarkably change
of serum profile of amino acids at day 7 and 12. The explanation
for this change is that arginine or glutamine supplementation will
change carbohydrate metabolism, amino acid metabolism, and
lipid metabolism, leading to the change of serum profile of amino
acids [26–28]. Intriguingly, dietary arginine or glutamine supple-
mentation significantly increases serum Gln content and AAI,
which are lowered in our DSS-induced colitis model. This might
be one of possibility that arginine or glutamine supplementation
alleviates the colonic damage in mice caused by DSS. However,
the metabolic profile in tissue and urine after arginine or
glutamine supplementation merits further exploration in IBD.
Similar to previous studies [14,29], DSS decreases colonic T-
SOD activity in mice. Arginine supplementation reverses this
Figure 7. Activation of colonic MLCK-MLC20 pathway. A: Immunoblotting of colonic MLCK-MLC20 at day 7. B: Quantification of relative MLCK
abundance from data shown in A. C: Quantification of relative MLC20 abundance from data shown in A. D: Immunoblotting of colonic MLCK and
MLC20 at day 12. E: Quantification of relative MLCK abundance from data shown in D. F: Quantification of relative MLC20 abundance from data
shown in E. Mice were treated with normal drinking (control), or distilled water containing dextran sulfate sodium (DS), or dextran sulfate sodium
water with dietary 0.4% arginine supplementation (DSS+0.4% Arg), or dextran sulfate sodium water with dietary 1.5% arginine supplementation
(DSS+1.5% Arg), or dextran sulfate sodium water with dietary 0.5% glutamine supplementation (DS+ 0.5% Gln), or dextran sulfate sodium water with
dietary 2.0% glutamine supplementation (DS+ 2.0% Gln). Data are presented as mean 6SEM, n= 5, with a-c used to indicate a statistically significant
difference (P,0.05, one way ANOVA method). MLCK: Myosin light-chain kinase. MLC20: Myosin light chain 20.
doi:10.1371/journal.pone.0088335.g007
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decline at day 12 in DSS-induced colitis model, which may explain
the beneficial role of arginine supplementation on colonic
oxidative injury caused by DSS in mice. Indeed, our previous
study also showed that arginine supplementation increases serum
T-SOD activity in porcine circovirus infected pregnant mouse [30]
and pig [31]. However, arginine or glutamine supplementation
has little effect on colonic CAT and GHS-Px activities in DSS
treated mice, thus it is interesting to explore the effect of arginine
or glutamine supplementation on colonic reactive oxygen
metabolities, such as superoxide, hydroxyl radical and hydrogen
peroxide, because these substances are higher in IBD model than
its control [14,32].
Intriguingly, arginine or glutamine supplementation increases
the production of colonic inflammatory cytokines, including IL-1b,
IL-17, and TNF-a at day 7. This observation is much difference
from the previous reports that arginine or glutamine supplemen-
tation significantly lowers these cytokines production [8,9,23]. The
explanation for this difference remains unknown; perhaps it is
related to the high dose of arginine (1.5% in diet) or glutamine
(2.0% in diet) supplementation. In our other study, we also
observed that higher (2.0%) dose of glutamine supplementation
significantly promotes the pro-inflammation expression, compared
to the lower dose of glutamine supplementation in the spleen in
Pasteurella multocida infected mice[25]. Indeed, 0.4% arginine
supplementation lowered the expressions of IL-17 and TNF-a,
compared to the DS group at day 12. These results indicated that
we should play more attention on the dose of arginine or
glutamine supplementation. However, it remains to explore the
effect of arginine or glutamine supplementation the production of
anti-inflammatory cytokines (IL-4, IL-10). Another possibility is
that DSS contamination on colonic tissues potently inhibits the
RT-PCR amplification [33].
Glutamine supplementation inhibits the activation of NF-kB at
day 7. Pervious compelling study also showed that glutamine
significantly suppresses p65 protein expression in the colon when
compared to that of colitis mice without treatment by glutamine
[34]. However, it is interesting to explore the effect of glutamine
supplementation on other components of NF-kB pathway in DSS-
induced colitis model because glutamine could counteract
activation of this pathway at multiple levels[7]. At day 12,
arginine or glutamine supplementation could inactivate the
colonic PI3K-Akt pathway, which adds more evidence to previous
study [35] [36]. However, in DSS-induced colitis model, it will be
fruitful to understand the effect of arginine or glutamine
supplementation on other colonic signaling pathways, such as
signal transducer and activator of transcription (STAT), activating
protein-1 (AP-1), and peroxisome proliferator-activated receptor-c
(PPARc), which play central role in intestinal inflammation [7].
Interestingly, arginine supplementation inhibits the activation of
MLCK. MLCK is involved in cytokine-mediated regulation of the
tight junction structure, resulting in reorganization of tight
junction proteins [37]. In our study, we also found that arginine
increases the expression of claudin-1 at day 7 after DSS treatment.
Figure 8. Tight junctions expression in the colon. Claudin1, occludin, and ZO-1 were analyzed with immunohistochemistry analyses in DSS-
induced colitis model at day 7 and 12. Mice were treated with normal drinking (control), or distilled water containing dextran sulfate sodium (DS), or
dextran sulfate sodium water with dietary arginine supplementation (Arginine), or dextran sulfate sodium water with dietary glutamine
supplementation (Glutamine). The dosage of arginine supplementation at day 7 is 1.5%, while it is 0.4% at day 12. The dosage of glutamine
supplementation at day 7 is 2.0%, while it is 0.5% at day 12. ZO-1: zonula occluden-1.
doi:10.1371/journal.pone.0088335.g008
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Thus, it remains to know the effect of arginine supplementation in
tight junctions function in DSS-induced colitis model.
In conclusion, the present study provides in vivo evidence that
serum amino acids profile changes in DSS-induced colitis model.
Meanwhile, arginine or glutamine supplementation can improve
clinical and biochemical parameters, involving in NF-kB, PI3K-
Akt and MLCK signaling pathways, in a murine colitis model of
injury and repair with similarities to human UC. Moreover, the
beneficial role of arginine or glutamine on DSS-induced colitis
model depends on the supplemental dosage. The substantial effect
of arginine or glutamine on intestinal inflammatory signaling
pathways suggests the potential for broad applicability in other
diseases associated with inflammation.
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